(Reuters) - Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

Matt Savino, Carlyle global head of capital markets, expects the IPO market to improve in 2025. He is on "Bloomberg ." ...

BofA analyst Craig Siegenthaler lowered the firm’s price target on Carlyle (CG) to $47 from $50 and keeps an Underperform ...

The Carlyle Group Inc. (NASDAQ:CG), a global investment firm with a market capitalization of $18.52 billion, has recently ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

SOMERVILLE, Mass., February 21, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global ...

The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

Markets worldwide defied expectations in 2024 led by the dominating performance of mega-cap technology stocks known as the ...

The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...

Bank of America Securities analyst Craig Siegenthaler maintained a Sell rating on Carlyle Group (CG – Research Report) yesterday and set a ...